Safety and heart rate changes in Covid-19 patients treated with Remdesivir.

OBJECTIVES: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir.
METHODS: We present a case series of 52 patients who underwent daily electrocardiogram (ECG) examination after Remdesivir administration.
RESULTS: Compared to baseline, a significant heart rate reduction was observed after initiation of Remdesivir; however, no case of severe bradycardia or arrhythmias leading to significant clinical complications or Remdesivir discontinuation occurred. Heart rate reduction was proportional to baseline heart rate values (r=0.75, p<0.001). By multivariate analysis, a less severe clinical presentation of Covid-19 (beta=0.47, p<0.01) was related to lower heart rate levels observed after Remdesivir administration.
CONCLUSIONS: Despite a significant reduction in heart rate observed after Remdesivir administration, no severe cardiovascular toxicity was observed in Covid-19 patients, even in the case of cardiovascular comorbidities.

Introduction

Remdesivir is the only antiviral drug currently approved under emergency use authorization to treat patients hospitalized for mild and moderate COVID-19 (Beigel et al., 2020). Isolated cases of cardiac rhythm abnormalities have been reported in patients on Remdesivir, including sinus bradycardia and QTc interval-prolongation (Gubitosa et al., 2020; Gupta et al. 2020), warranting close cardiac rhythm monitoring during Remdesivir administration.

Therefore, we aimed to prospectively assess, in a cohort of Covid-19 patients treated with Remdesivir, the occurrence of heart rate abnormalities and their potential clinical predictors through serial electrocardiogram examination.

Methods

From October 1, 2020, to February 28, 2021, 52 consecutive patients with COVID-19 treated with Remdesivir underwent serial electrocardiogram examination after antiviral administration. Electrocardiograms were recorded at baseline (T0), each day for the following five days (T1-T5), and at discharge (Td). Minimum, maximum, and heart rate changes over time were collected. The occurrence of bradycardia, symptomatic bradycardia, QTc prolongation, and cardiac rhythm abnormalities of any kind were reported.

Bradycardia was defined as a heart rate<60 bpm, following the definition of the National Institute of Health (Rijnbeek et al., 2014).

Symptomatic bradycardia was intended to associate a heart rate <60 bpm and the development of clinical manifestations of syncope or presyncope, transient dizziness or light-headedness, heart failure symptoms, or confusion states resulting from cerebral hypoperfusion attributable to slow heart rate (Kusumoto et al., 2019). The occurrence of bradyarrhythmias (sinus pause, sinus node arrest, tachycardia-bradycardia, atrioventricular block, atrial flutter, atrial fibrillation) was also noted.

For each patient, the duration of the QT interval at every ECG was recorded on the case report form. Corrected QT (QTc) was calculated in relation to heart rate according to Bazett's formula (Bazett, 1920). QTc prolongation was defined as the detection of values above the normal range (440 msec for men, 460 msec for women) (Crotti, 2013).

Remdesivir was discontinued in the case of i) clinical signs of symptomatic bradycardia (as defined above) or ii) laboratory findings of worsened kidney and/or liver function noticed by the attending physician. A global evaluation of the patient's condition that kept age, the severity of disease, comorbidities, comedications into account was also requested.

Patients were enrolled in the study under the condition of having at least three ECGs performed in the course of Remdesivir, besides those recorded the days of admission and discharge.

Demographics and clinical data were recorded. The clinical severity of Covid-19 was assessed according to NIH Coronavirus Disease 2019 (Coronavirus Disease 2019 COVID-19 treatment guidelines, 2020) (https://www.covid19treatmentguidelines.nih.gov/.).

Statistical analysis

Data are presented as frequency (%) for categorical variables. For continuous variables, results are reported as means ±standard deviation or as median (Inter Quartile Range, IQR), according to their parametric or non-parametric distribution, respectively. The Student's t-test and the Mann–Whitney U-test were used to compare continuous variables with normal and non-normal distributions. The Chi-squared test or Fisher's exact test were used to compare categorical variables. Linear correlation was evaluated by Pearson's test. Repeated measures were compared with the ANOVA test. Multiple stepwise forward regression analysis was used to assess the bias of possible principal confounders. A p-value <0.05 was considered statistically significant.

Results

Mean hospital stay was 18±9 days, 56% of patients enrolled were male, 76% were >50-year old, 53% had at least one major cardiovascular comorbidity, 57% were hypertensive, 24% diabetic, 7% had ischemic heart disease, and 77% (N 40) a severe clinical presentation of Covid-19. All but one of the patients were discharged alive; one patient died from septic shock.

A median of five ECGs (IQR 2) per patient was overall recorded in the study population.

Compared to baseline, a significant reduction of heart rate was observed after administration of Remdesivir (ANOVA p<0.05, Figure 1 a) from 85±16 bpm at baseline to 70±18 bpm at discharge; heart rate reduction was already statistically significant on the first day of treatment (ANOVA p<0.001). No case of symptomatic bradycardia or arrhythmias leading to clinical complications or Remdesivir discontinuation was observed. No case of QTc prolongation occurred.

Figure 1

a) Heart rate changes (mean±95%CI) after Remdesivir administration (ANOVA p<0.01). b) Changes in heart rate after Remdesivir were proportional to baseline levels.

Mean lowest heart rate recorded was 61±11 bpm, mean heart rate reduction observed was 24±16 bpm: mean heart rate reduction was higher in men than in women (28±16 bpm vs. 18±14 bpm, p<0.05). Heart rate reduction was proportional to baseline heart rate values (r=0.75, p<0.001, Figure 1b).

The result of a multivariate analysis including age, gender, cardiovascular risk factors, presence of ischemic heart disease, atrial fibrillation, baseline heart rate, troponin, renal function values, cardiovascular therapy (beta-blockers, amiodarone), and need for ventilation, showed that the only factor significantly related to lower heart rate levels observed after Remdesivir administration was a less severe clinical presentation of Covid-19 (beta=0.47, p<0.01)

Discussion

Cardiovascular implications of Sars-COV-2 infection have been widely documented and associated with poor prognosis, which can be worsened by underlying cardiovascular diseases (Azavedo, 2021).

Assessing potential adjunctive drug-related cardiovascular toxicity is thus crucial, especially in the absence of data regarding the cardiovascular toxicity of some of the few therapeutic options available such as Remdesivir, an antiviral prodrug polymerase with inhibitory activity against the viral RNA-dependent, RNA polymerase of the SARS-CoV virus (Beigel et al., 2020). Studies in vitro demonstrated a pronounced affinity of Remdesivir for human cardiomyocytes, with higher local concentrations and activity (Choi et al., 2020), partly explaining the reported pro-arrhythmic activity of Remdesivir.

The potential effect of a five-day treatment regimen with Remdesivir on cardiac rhythm has been already highlighted. Besides isolated reports of transient bradycardia, detected by clinical observation or with a single ECG performed in the course of antiviral treatment (Barkas et al., 2021, Gubitosa et al., 2020), in several cohort studies, heart rate has been monitored by waist pulse before and during Remdesivir administration (Pallotto et al., 2021) or, just two ECGs were collected before and after antiviral treatment (Attena et al., 2021).

In this paper, data collected from a cohort of patients who underwent daily ECG monitoring in the course of Remdesivir administration are presented.

Our data seem to confirm previous observations on heart rate reduction after Remdesivir administration, although never associated with bradycardia, symptomatic bradycardia, or significant QTc prolongation leading to Remdesivir discontinuation.

Notably, higher heart rate reduction was observed in subjects with higher baseline heart rate, thus supporting the hypothesis that the principal driver in heart rate reduction was not Remdesivir but, presumably, the improvement in baseline clinical conditions responsible for tachycardia (fever, hypoxia, inflammation, anxiety). Moreover, the phenomenon was mainly observed in patients with a less severe clinical presentation, a finding that may further reassure clinicians about the absence of contraindications about the use of Remdesivir in critical patients, at least regarding cardiac function.

As well, no significant correlation was observed with age, cardiovascular risk factors, comorbidities, cardiovascular drugs, or troponin levels.

The limited number of subjects and the absence of a Remdesvir-free control arm are the main limitations of this study.

Nevertheless, as far as can be observed in our sample, Remdesivir showed a favorable toxicity profile even though associated with a significant heart rate reduction. Further research is needed to confirm this preliminary observation on a larger number of subjects.

Conclusions

Despite a significant reduction in heart rate observed after Remdesivir administration, no severe cardiovascular toxicity was observed in Covid-19 patients, even in the case of cardiovascular comorbidities.